Align Technology, Inc. (NASDAQ:ALGN) had its target price upped by equities research analysts at Goldman Sachs Group, Inc. (The) to $210.00 in a report issued on Friday, The Fly reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. Goldman Sachs Group, Inc. (The)’s price objective suggests a potential upside of 13.61% from the stock’s current price.

A number of other equities research analysts have also weighed in on ALGN. Stifel Nicolaus reaffirmed a “buy” rating and issued a $205.00 price objective (up previously from $200.00) on shares of Align Technology in a report on Monday, August 7th. Robert W. Baird reaffirmed a “buy” rating on shares of Align Technology in a report on Tuesday. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Align Technology in a report on Monday. Bank of America Corporation raised Align Technology from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $175.00 to $193.00 in a report on Friday, July 28th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $199.00 price objective (up previously from $194.00) on shares of Align Technology in a report on Friday, July 28th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Align Technology has an average rating of “Buy” and a consensus target price of $179.82.

Align Technology (NASDAQ ALGN) traded up 0.17% during trading on Friday, reaching $185.17. The company had a trading volume of 259,816 shares. Align Technology has a 1-year low of $83.27 and a 1-year high of $186.10. The stock has a market capitalization of $14.84 billion, a price-to-earnings ratio of 63.41 and a beta of 1.55. The firm has a 50-day moving average of $174.44 and a 200-day moving average of $142.87.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.85 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.12. Align Technology had a return on equity of 23.87% and a net margin of 19.18%. The company had revenue of $356.50 million for the quarter, compared to analyst estimates of $343.43 million. During the same quarter in the previous year, the company earned $0.62 EPS. The firm’s revenue for the quarter was up 32.3% compared to the same quarter last year. On average, analysts anticipate that Align Technology will post $3.40 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Align Technology, Inc. (ALGN) Price Target Increased to $210.00 by Analysts at Goldman Sachs Group, Inc. (The)” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/15/align-technology-inc-algn-price-target-increased-to-210-00-by-analysts-at-goldman-sachs-group-inc-the.html.

Several institutional investors have recently modified their holdings of the stock. Navellier & Associates Inc raised its position in shares of Align Technology by 4.5% during the 2nd quarter. Navellier & Associates Inc now owns 68,761 shares of the medical equipment provider’s stock worth $10,322,000 after purchasing an additional 2,963 shares during the last quarter. Sentry Investment Management LLC acquired a new position in Align Technology in the 2nd quarter valued at $882,000. Ashford Capital Management Inc. raised its holdings in Align Technology by 46.9% in the 2nd quarter. Ashford Capital Management Inc. now owns 6,941 shares of the medical equipment provider’s stock valued at $1,042,000 after acquiring an additional 2,216 shares during the last quarter. Toronto Dominion Bank raised its holdings in Align Technology by 3,163.1% in the 2nd quarter. Toronto Dominion Bank now owns 25,583 shares of the medical equipment provider’s stock valued at $3,840,000 after acquiring an additional 24,799 shares during the last quarter. Finally, Cetera Investment Advisers acquired a new position in Align Technology in the 2nd quarter valued at $470,000. Hedge funds and other institutional investors own 81.72% of the company’s stock.

About Align Technology

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

The Fly

Analyst Recommendations for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.